

Canada and Japan: Opportunities for Increased Linkages and Cooperation in RM

JETRO-CCRM Workshop on Japan's RM Market
January 29th, 2016, Toronto

Michael H. May PhD
President & CEO



Government of Canada
**Networks of Centres
of Excellence**

Gouvernement du Canada
**Réseaux de centres
d'excellence**

CCRM – Mission, Vision

Mission

Sustainable Health and Economic Impact Through Global Collaboration in RM

Vision



Preferred global destination

for the best people, technologies, clinical trials, companies and investments in RM



Premier global enabler

of clinically-tested, revolutionary new medical therapies and foundational technologies


Key Corporate Metrics

1. **Health Outcomes** – Accelerate Clinical Translation
2. **Job Creation** – Create and Attract Companies
3. **Return on Investment** – Achieve Sustainability


Key Stakeholder Engagement & Outcomes



Key Elements of the CCRM Model



Core Activities & Business Units



Leveraging Our Academic Partners

CANADIAN INSTITUTIONS



CANADIAN PARTNERS



Medicine By Design



Centre for Cell and Vector Production



Engaging Our Industry Consortium

TOOLS & DEVICES



THERAPEUTICS




20 Existing Projects
20 Proposed Projects

\$40M *BridGE@CCRM*



Analytics & Assay
Development
(in development)

Focus on Company Creation, Phase 1 Trials and Bioprocessing



CCRM's New RM Cluster at MaRS




40,000 ft² Co-Location of:

- CCRM
- BridGE@CCRM
- GMP Manufacturing Facility (GMP)
 - ~10 clean rooms
 - 2 vector production suites
 - Phase I/II trials
- Headquarters:
 - \$25M Ontario Institute for Regenerative Medicine (OIRM)
 - Disease Teams
 - \$115M Medicine by Design
 - Synthetic Biology
 - Proposed RM Fund (RMIF)

CCRM V2.0 and 3.0

Vibrant Ecosystem + Sustainability + Global Reach



* AMS – Advanced Manufacturing Solutions

CCRM V3.0 – a Sustainable Global Network



Phase 1: Set-up local hubs

Phase 2: Local hubs establish global hub

Local Hubs

People



Funding



Facilities



ACADEMIC

INVESTOR

INDUSTRY

NFP

FP

Charity

Why Create Local Hubs Around Global Cooperation

1. RM is complicated; there is less funding; and time is of the essence
2. Achieves critical mass and scale
3. Creates synergy - regions have some, but not all, intellectual property (IP), expertise and resources
4. Enables access to markets and patients
5. Facilitates and supports industry-building activities (e.g., development of standards, data sharing)

Funding
Industrialization
Market Access
Gateway to Asia



Scientific
Excellence



Company Creation
Bioprocessing
Phase I and Pivotal Trials
Gateway to NA and EU



Progress To-Date

1. Industry - Ongoing Projects & MOU with FIRM
2. Academia – Conferences & MOU with Leading Institutions
3. Investors – Ongoing Meetings in Support of RMIF
4. Company Creation – Evaluation of Technologies with 360IP Japan
5. CCRM Japan – Workshop Among Industry, Academia & Regulators

Summary



1. CCRM has established a collaborative and capital-efficient commercialization model
2. In 4 years, CCRM has demonstrated that a specialized and coordinated commercialization platform can attract partners, deliver new funding and generate impact
3. To achieve sustainability, CCRM takes a share of promising opportunities, acting like a technology-focused investor (not a granting agency)
4. CCRM plans to address the complexity, resource limitations, time constraints and untested markets of RM by building a global network of like-minded commercialization hubs
5. CCRM is actively engaging partners around the world in support of its global network